FDA accepts Palvella's QTORIN 3.9% rapamycin gel NDA for priority review, PDUFA set for Feb 28, 2027

Palvella Therapeutics announced the FDA accepted its New Drug Application for QTORIN 3.9% rapamycin anhydrous gel and granted priority review, with a PDUFA action date of February 28, 2027. The company targets commercial launch in the first half of 2027, pending approval.

Detected & updated continuously · Source: Nebula